Novel method could optimise beta-blocker synthesis
By Catherine Eckford (European Pharmaceutical Review)
New biosimilar pathways – key takeaways from the EMA’s draft reflection paper
By Vladimir Murovec (Osborne Clarke)
Eli Lilly genetic medicine acquisition to address cardiovascular risk
By Catherine Eckford (European Pharmaceutical Review)
UCB commits major US biologics manufacturing investment
By Catherine Eckford (European Pharmaceutical Review)
The rise of multimodal language models in drug development
By Alessio Zoccoli, Dr Carlos Velez, Dr Remco Jan Geukes…